Engineered immune cells take aim at tough lymphomas in first human test
NCT ID NCT03602157
First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack cancer cells carrying the CD30 protein. Some of these cells are also engineered to produce CCR4, a protein that helps guide them to the tumor. The main goal is to find a safe dose and understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Genetically modified T cells (CAR T-cells) targeting CD30, with or without added CCR4 protein
What this could lead to
If successful, this could lead to a new treatment option for patients with hard-to-treat lymphomas that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 43 participants, focused on safety and dosing. It is too soon to know if the treatment will work, and there are risks of side effects like cytokine release syndrome or nerve toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.